there are a couple winners right now. the u.s. natural gas fund and the market vectors gold miners. there was a winner as well in the biotech sector but now it is a loser, down half a percent on the trading session like a lot of other things in this market. >> a real choppy start to the trading year. see you when you get back home. that does it for "power lunch." >> "street signs" begins now. hello. welcome to a very special bicoastal edition of "street signs." i'm mandy drury. big story here at hq is the markets. let's take a look at what the dow is doing. it is currently down by exactly 100 points. however, brian sullivan is over there live in san francisco, a mile away from what's going on on wall street. he's at the 32nd annual jpmorgan health care conference and the biggest names in health care are there. he has a jam-packed can't-miss lineup for us, right? tell us exactly what you have on tap. >> you really sold it.

i hope i can deliver on that promise. thanks very much. we have been here all morning but i saved a stat for our "street signs" viewers and listeners which is really going to make your head explode and one of the reasons we're here. this comes courtesy of jpmorgan chase who is obviously putting on the conference, which is this. so far this year, i know it's extremely early in the calendar 2014, but 94% of health care stocks have outperformed the s&p 500. in other words, they are outperforming and they are outperforming in a big way, and a number of those names have been on cnbc all day and will be here this hour as well. coming up in a few minutes, we have one of the biggest biotechs of them all. their ceo will join us. also, the $21 billion company perego which recently moved its headquarters to ireland. we will talk about them and how they are skiing teeing the cons economy. then another name not familiar, a company that is not a biotech per se but makes its money finding office space for biotechs. got a greater than 4% dividend.

a.r.e. is the ticker. that ceo coming up as well. we'll be here all hour. i would say sunny san francisco but i don't know because i'm inside this hotel. >> a little bit like us inside the studio. sounds like we have a whole lot more than just the hour will afford us but we will do our very best. back to what the markets are up to. as i mentioned, the dow is touching its lowest level in nearly three weeks, down by exactly 100 points. this is also the fourth straight loss for the dow which could be the biggest losing streak in over a month. which means the dow, if you do the math very quickly, has only had two up sessions so far in 2014. why, what's going on? lower oil prices weighing on the stock prices. you can see here, down by 1.5% is the s&p energy sector. as for the nasdaq, it did manage to raise its year-to-date losses earlier in the session. that now is completely gone out the window. it is down by .7%. the brightest on the s&p 500

today, though, is beam. this is as japan's suntory is buying the liquor company for $16 billion. that makes suntory the world's largest maker of distilled drinks. although there's a lot of red behind me, beam is certainly a very bright spot. okay. the question is whether or not what is going on today is it just a one-off or sign of a winter slump? joining us, wells capital management's jim paulson, equity managements. jim, what do you think about the start to 2014? >> it's not too bad. i think it's kind of good in a way. we have sort of stopped the relentless advance of stocks for awhile, give people pause, make them a little suspect again, reduce optimism, give earnings a chance to catch up. we have taken 20 basis points out of the ten year yield from its high at around 10%. it isn't just roaring ahead putting more pressure on stocks. maybe allow the earnings season to come through, see where we're at. actually, i think we are going to go higher before we have any

major correction. that's my best guess. >> but there are a lot of negative things going on out there. for example, linda, there was a goldman sachs bearish call this morning on valuations. you had a lot of bad news coming out of the retailers. you know, i'm just wondering whether or not what we're seeing today is all of those fears starting to pile on the market and if the fed is going to be less market-friendly, is it a possibility we could get a correction here? >> hopefully we get a correction. i agree with jim on this. we finish the year much higher than we thought we would at fed rated investors last year. we think we borrowed from this year. a relentless run-up means you will have a nasty, nasty correction, maybe even a bear market in the summer. would be perfect if we got a 10% correction now. foolish i think to worry about retail sales. we have to decide what are we going to worry about. is the market showing the economy's too strong, we need to worry about interest rates going up, or is the market suggesting that now there's weakness and we

need to worry about a recession. we see neither one. in fact, we see an accelerating growth with still low inflation and that is actually a very bullish outcome. >> you think if we do get a correction which is a possibility, this is a good thing. you are waiting to buy? >> we're actually, we don't suggest that anyone should time the market that closely. we have suggested that we will finish this year at s&p 2100 and are bullish, we are bullish all along. i wouldn't want to be cute with the market and time it. but if we see a meltup which is the worst thing we could imagine, then we would say that would be a good time to get your powder ready and dry because you are going to get a nasty, nasty correction which will be very buyable. >> jim, here's a thought. if we continue to see some weakness in the market and we continue to see this negative news coming out of particular retail sector, which really speaks to the health of the u.s. consumer, do you think that might stay the fed's hand a little? will it affect monetary policy? >> i think, mandy, that if the data would have to go fairly weak right now before the fed

would probably change its course that it's put in motion but it certainly could. if it goes weak enough, the fed will come out and announce they will suspend the tapering or at least slow the pace down. i really think that the driver's not going to be the fed. the driver's the economy. if economic reports stay reasonable to better than expected, then i think this market will go up. it will be interesting to see, for example, if after today, if we stay down here or go a little lower this week, how many buyers come in with a chance to get into this market that haven't had that opportunity, been waiting for one. i think there's a lot of money in the sidelines waiting for an entry point. that's why i think we're not there yet to have a major correction. >> certainly all that money on the sidelines is going to be watching this earnings season very closely. linda, i have a great stat. let me bring it up on the screen for our viewers. for the s&p, there have been 108 negative preannouncements for eps for the q-4 versus 11

positive eps-3 announcements. only 11. what does that say to you? is that setting expectations low? or is this really something to be worried about? >> it's really an interesting statistic. i have not seen anything that can really explain why it's so incredibly bad because we know that historically, when you have a lot of negative versus positive preannouncements, that sets the market up to have a nice run into earnings season because many companies can surprise to the upside. i have seen that many of these negatives have come out of the technology sector, however, so it may be more heavily weighted in one or several sectors. >> what about you, jim? what are your expectations for the earnings season and which sectors do you think will stand out, which will be bad? >> i guess one thing i always used that works pretty well is when i see street estimates on real gdp for the quarter rise during the quarter, which is exactly what we've had here, we came into the fourth quarter thinking relatively modest growth after big inventory build

in the third and you have seen nothing but people revising up gdp estimates. what i find is when people revise up gdp estimates, they are typically under forecasting the earnings season. so i think we will have an outperforming season primarily because people have underestimated the strength in the fourth quarter in the economy. i really like the manufacturing area. i think you will see some good numbers coming out of the industrials areas where certainly the transports are suggesting there's good numbers there. i'm with linda a little, i think technology's going to show some weakness and i'm a little concerned about consumer cyclicals or the retail sector as a whole. >> i suppose if you set expectations low enough, the only way is up, right? thank you both very much for joining us. coming up on the show, we will head back out to san francisco for brian's one-on-one interview with the ceo of biogen. that stock hitting an all time high today. perfect timing. is there much more room for it to run? then later on, target's ceo speaking exclusively to becky

quick of cnbc about that massive data breach. is their information safe? i'm beth... and i'm michelle. and we own the paper cottage. it's a stationery and gifts store. anything we purchase for the paper cottage goes on our ink card. so you can manage your business expenses and access them online instantly with the game changing app from ink. we didn't get into business to spend time managing receipts, that's why we have ink. we like being in business because we like being creative, we like interacting with people.

so you have time to focus on the things you love. ink from chase. so you can.

welcome back. let's take a look at the markets again. ten sectors on the s&p are lower but the least worst today has been the tech sector which has actually held up pretty well so far this year. the best s&p sector for the new year, though, is health care. which means time to get back to brian at the jpmorgan health

care conference with a first on cnbc interview with the biogen ceo. >> thank you very much. yeah, incredible year so far, like we said at the top of the show. 94% of s&p health care stocks have outperformed the s&p 500 so far this year. it's early but a heck of a stat. one of the biggest biotechs out there has been our next company, biogen, the stock down today but effectively doubled over the past 12 months. the ceo of b-i-i-b joins us now. congratulations. the stock has done great over 12 months but there's a problem. with good returns come greater expectations from investors. how is business? how's the economy? >> well, business is going great. we had a great 2013, as you said. we launched a great new drug from m.s. patients. 2014 looks to be a very interesting year for us. hopefully we will be able to launch in the european union and europe. we have three other drugs that are awaiting approval at the fda

so assuming those drugs are approved, we will be able to have three more launches here, two for hemophelia, one for multiple sclerosis. 2014 looks great. >> interesting choice of words, interesting year. doesn't necessarily mean good year. you think it will be? >> look, i think we are poised to have a very good year in that way. three drug launches, three and a half drug launches, phase three readout on a drug that we have hopes for for multiple sclerosis and about six readouts on our phase two compound. very busy year this year. >> analysts were optimistic about your new m.s. drug but there was some concern that it will eat into other m.s. franchises that you have. is it going to be sort of layered on top or will it eat a little bit into some of your other m.s. business? >> i can tell you what we know so far. about 25% of the patients coming on were not on any previous treatment. so it is expanding the multiple

scler sclerosis market. about 75% were on previous treatments and they seem to be coming from all other m.s. drugs, proportionate to the market share of those drugs. >> so no negative implication necessarily on the other m.s. franchises. >> we sell avanex for the treatment of m.s., that seems to be doing very well. we have waiting at the fda for approval a drug which is a longer acting version which can be administered as infrequently as once every two weeks. we think that will give that franchise a little boost. and we have a drug which is a very efficacious drug. those seem to be doing well. >> a lot of cash flow and some analysts have asked me to ask you, when's the dividend coming? you got a strong free cash flow now. >> we do have a free cash flow. if you look at what we've done over the past five or six years, we generated about $10 billion in excess cash.

we have returned about $6 billion of that to investors in the form of stock buy-backs and we did those at a very attractive price. >> they like cash, george. more clamoring for dividend, perhaps. >> we used about $3 billion of that to acquire tisavery and $1 billion of that to bolster the pipeline. if you look at the value that $1 billion has returned, it's tremendous. most of these products that we are getting approved last year, this year, came from that in licensing portfolio. we tend to keep to that strategy of capital allocation. >> 200 companies here, many of them small up and comers, we highlighted a few of them on cnbc today. do you expect to walk away from here with a deal? are you here shopping for smaller companies? >> we have quite a significant business development group out here. they're busy -- >> you're looking. >> we are actively looking. we are always looking. there are many good companies here, as you say. there are a number of interesting compounds that are developing. we are in active discussions. >> what's changed?

you took over the company in mid-2010, the stock took off. what's different today? >> several things. number one, we had five readouts of phase three trials, four of those were successful. so number one, we have more products than we used to have. the company is focused, much more focused than it used to be and the company's really i think, it has a great leadership team and is executing on all fronts. >> real pleasure. thank you for joining us on cnbc. >> thank you very much. it's interesting, mandy, these are some of the hardest interviews we do. it's highly technical. but what's interesting, the core is very simple. when you get into it, no matter what they do, they need drugs that work and they need the drugs that work to be sold and prescribed by doctors and to get reimbursed. that's the fundamental aspect. we will talk to a $21 million cap company, they just moved headquarters to ireland, later in the show. >> they are trying to make our

lives and health better, right? we will get back to you shortly. still ahead, from sizzle to fizzle. shares of soda stream hitting a 52-week low. is there any pop left in the stock? we will duke it out. then back out to san fran for two can't-miss interviews from the jpmorgan health care conference. we will talk to a drug maker that is behind a lot of things you have right now in your medicine cabinet. it's also a named jim cramer loves. then who is profiting from the biotech building boom? looking at covered call strategies to generate income? with fidelity's options platform, we've completely integrated every step of the process, making it easier to try filters and strategies... to get a list of equity options... evaluate them with our p&l calculator... and execute faster with our more intuitive trade ticket. i'm greg stevens, and i helped create fidelity's options platform. it's one more innovative reason serious investors are choosing fidelity. now get 200 free trades when you open an account.

afghanistan, in 2009. on the u.s.s. saratoga in 1982. [ male announcer ] once it's earned, usaa auto insurance is often handed down from generation to generation. because it offers a superior level of protection. and because usaa's commitment to serve current and former military members and their families is without equal. begin your legacy. get an auto insurance quote. usaa. we know what it means to serve. there's nothing like being your own boss! and my customers are really liking your flat rate shipping. fedex one rate. really makes my life easier. maybe a promotion is in order. good news. i got a new title. and a raise? management couldn't make that happen. [ male announcer ] introducing fedex one rate. simple, flat rate shipping with the reliability of fedex.

[ male announcer ] introducing fedex one rate. thmortgage didn't start here. it began on her vacation in europe. someone stole her identity and opened some credit cards in her name. checking her experian credit report and score allowed her to better address the issue...and move right in. experian. if you have a business idea, we have a personalized legal solution that's right for you. with easy step-by-step guidance, we're here to help you turn your dream into a reality. start your business today with legalzoom.

welcome back to "street signs." a response to barrington capital's criticism that a spin-off of the red lobster chain is not enough to enhance shareholder value. take a look at this statement here. darden restaurants saying darden's board of directors and management team are focused on creating value for all shareholders. we are confident that our plan together with the actions we are taking to enhance guest experience and reinvigorate demand will lead to improved performance in our restaurants and substantially increase value for all shareholders. remember, barrington capital making the statement, the assertion that perhaps spinning

off or restructuring some of the assets will help unlock shareholder value. the response to those concerns. back to you. >> we can see the shares down 1.7% on a broadly lower day. the dow is now down by 124 points. shares of soda stream are down more than 20% today after the company lowered its fiscal 2013 forecast due to a weaker than expected holiday season. this is all coming as the company announced actress scarlett johansson will be the star of its super bowl commercials. can she give soda stream a lift? let's talk some numbers. carter worth of oppenheimer joins us, andy busch joins us on the fend mentundamentals. great to have you with us. let's talk about the stock. andy, let's start with you. do you see any reason to own soda stream after this announcement? >> well, you know, plug in your droll comment here, lost their fizz, out of gas, whatever you want to say about soda stream, but they were a darling of the market back in the first six months of last year.

clearly the last two quarters, they have missed on earnings and really, that's the problem. when you get a company that says for instance, in october they said adjusted net income would be $65 million, it came in at $52.5 million. that's a 20% miss. that's why the stock's down 20% and it's down about 50% from the highs back in may. so for right now, i would say it's an interesting company. i like the product. i like the product design. but clearly, until they can go back and reestablish some confidence with the markets about what they're predicting for their sales, they will have trouble. >> that's the fundamentals side. are we getting any confidence from the charts, carter? do you see the same problems as andy does? >> same as andy. look, this is an unmitigated disaster. it's not out of nowhere. the stock just as andy said has been on its way down since may, plunging from $80 to the print last week, then plunging in again today. it's a testament to not buying weakness. the relative strength matters.

the relative strength has been poor. if you look at the chart since the ipo, it is a perfect double top. it had a peak in june of 2011 at the 78 level, it peaked there again in '13. this thing is going to 30 from what we can see. >> going to 30. yeah. certainly is a double top there. you can see it very clearly. thank you so much, gentlemen, on soda stream. check out the online edition of "talking numbers" in partnership with yahoo! finance. that's what's going on out here in the market world. what's going on in the jpmorgan health care conference, brian? what have you got lined up for us? >> we have another ceo for you here. thank you very much. i've got some good news for you. fewer people are getting sick this year. last year was a very difficult flu season. this year, not quite as much. but that actually might be not so good news for our next guest. he will tell us whether it or isn't. joe papa, ceo of perrigo, p-r-g-o. you have a number of over the counter products. analysts are saying listen, flu

season comps are going to be very tough for you to match. give us an update. >> absolutely right, last year was a very strong cough/cold flu season, there were a number of patients affected. however, this year, we are seeing it's about a month behind. last year it started in december, ran through january. this year, we are seeing it now start to pick up, especially with the cold weather that we experienced on the east coast. >> we are lagging. unfortunately, it's like we're talking about the flu season ramping up, you think that it will be -- become a tougher flu season, just in a few weeks? >> the data we are seeing right now from all the data we see shows that it's really ramping up very quickly right now. can't expect exactly what is going to happen there but at least it looks like it's ramping up, very similar to last year, albeit a month behind. >> the reason we are talking about it, some of our viewers may be saying what are you talking to him about because you're not a household name but your products in stores, they are. you are a massive consumer

focused company but the name perrigo is not recognized and some investors i talked to said because of that, opportunities may be being overlooked by investors. is that a fair assessment? what can you do more importantly to change that? >> yeah. you are absolutely correct. people know that the store brand private label is a great alternative, gives the same safety and effectiveness as the national brand. however, usually saves the consumer 25% to 30% off the product. >> they don't know it's you. >> absolutely correct. so what we're doing is working with our large retailers to go out. one of the data points we just got our hands on, the most informed consumers, physicians, pharmacists, 72% of the time, they use store brand, not the national brand. as we go out and start to talk about that story, that message to our retailers but also to consumers, we think that will be an important driver for the future. >> that is good. 72%'s a big number. by my math that's almost

three-fourths. but do you plan to try to make it more of a household name? >> absolutely. absolutely. that's what we're working with. mostly through large retailers, to be fair. >> don't want to tick them off. >> right. they know we are probably about the top ten largest manufacturer of pharmaceutical products in the world as measured by tablets. every second, every day, somewhere in the world, 1400 people take a perrigo product but we have to get name out even more. >> you did a deal with elan from ireland. technically you are headquartered in dublin, ireland. how is that going to impact your tax structure and will it help profitability? and free cash flow? having a slightly different tax structure without being too wonky. >> absolutely. well, importantly, what we liked about elan is it give us a gateway to get into europe, to

additional activities in europe because we were excited about taking our version of quality affordable health care and bringing it in to europe and around the world. most of our sales today are about 80% u.s. based. it will lower our tax rate, to be clear. our tax rate prior to this transaction was in the 30% range. our tax rate will come down into the high teens rate. so that is a positive. but importantly, it gives us really a gateway to get into some of the other european countries and around the world. that's what's most important. >> two final questions to wrap up. one i just asked biogen, same thing. tax rate will go down so presumably free cash flow will go up. will you begin paying a dividend and especially with michigan and our viewers know, michigan's a state close to our heart. we go there a lot. what are your hiring plans? >> so we do have a dividend, a very small dividend. >> fractional. >> it admittedly is small. we are looking at utilizing our cash and we have a cash process, where we are looking at what can we do for additional acquisition. in my seven years, we have done

about 17 acquisitions. we think there is still good opportunities to bolt on another product category and bringing on the truck that we send to our next customer, whatever large retailer it may be. on the issue of hiring, we still have big plans for hiring both here in the united states but also in dublin as we now recognize that as our global headquarters. >> joe papa, a pleasure. thank you very much for joining us here on cnbc. i know you have been with jim cramer on "mad money." he likes perrigo and has been right. you're up over 55% over 12 months. have a great conference. not a household name, but a name that you probably buy the products for yourself and your family. they will try to make that name a little more top of mind with consumers. >> fantastic stuff. we have got of course two more ceos and one president to go. two ceos down, two more to go and a president. it's all happening on this show. on deck back here at the cnbc mothership, it is a "streak talk" upgrade-palooza.

then we kick it back out to san fran, where josh lipton will be digging in on some high tech health care names set to ipo. do not want to miss it. tdd#: 1-800-345-2550 trading inspires your life. tdd#: 1-800-345-2550 life inspires your trading. tdd#: 1-800-345-2550 where others see fads... tdd#: 1-800-345-2550 ...you see opportunities. tdd#: 1-800-345-2550 at schwab, we're here to help tdd#: 1-800-345-2550 turn inspiration into action. tdd#: 1-800-345-2550 we have intuitive platforms tdd#: 1-800-345-2550 to help you discover what's trending. tdd#: 1-800-345-2550 and seasoned market experts to help sharpen your instincts. tdd#: 1-800-345-2550 so you can take charge tdd#: 1-800-345-2550 of your trading. over the pizza place on chestnut street the modest first floor bedroom in tallinn, estonia and the southbound bus barreling down i-95. ♪ this magic moment it is the story of where every great idea begins. and of those who believed they had the power to do more. dell is honored to be part of some of the world's great stories.

that began much the same way ours did. in a little dorm room -- 2713. ♪ this magic moment ♪

let's bring you up to date on what the markets are up to. currently sitting around session lows. the dow is down for the fourth straight day, off by 125 points. so far this year, the dow has only had two up sessions. just keep an eye on what goes on from here. in the meantime, dominic chu is joining us. we will do an upgrade version. we don't like to focus on all the negative stuff. let's show the bright spots out there. there are a few. upgraded to overweight at morgan stanley. >> all about the cloud, all of these software companies are converting to cloud-based subscription models. this could be a driver as they go away from traditional selling you a piece of software and rather selling you license to keep on using it and downloading it and whatnot. that's one of the reasons analysts like that stock. >> garmin upgraded to outperform from perform at oppenheimer. >> these guys do wearable gps for runners, marine gps systems, golf gps systems for golfers like me.

all the new products, aviation products, could be growth drivers beyond just their traditional products. smartphones have made some gpss out of date. >> no excuse to get lost anymore. finish line being upgraded to buy. >> two things. basketball and running. those things are accelerating for the finish line. that's why some analysts like this particular stock. expect to see those particular drivers drive those sales. that's why those shares are up. >> let's take a look at wendy's reporting fourth quarter profit that was higher than street forecasts. >> this is interesting, too, because with wendy's, we are talking about a hyper competitive space in fast food but in this case, all those product refreshes, some of the upgrades going on there, they could help drive same store sales. the analysts here over again saying that this particular one, we could see same store sales grow from 2.5% to 3.5% for the year. again, positive trends at least for wendy's. >> a company we don't often talk about, nimble storage getting an

upgrade to outperform. >> in this case, they call it at least some positive feedback from the end users of these type products. with those shares up 10%, what they are saying in essence is that the recent pullback has shares poised from a valuation standpoint to gain there. they put a price target at least of $46 a share. you can see right there -- >> look at the one year performance there, even 100%. >> nice doubling. right there. >> okay. thank you so much for that, dominic chu. let's go back out to brian at the jpmorgan health care conference in san francisco. brian? >> you know, mandy, i have to listen to you moan and groan all the time about missing josh lipton. every day, where is josh lipton. aren't you jealous? i have josh right here. >> i'm jealous. hi, joshie. >> hey, mandy, how you doing? >> she says hi, joshie. >> i miss that accent. >> hello, joshie. we're out here, a lot of ceos. you're here because venture capital money sniffing around health care, they think, what,

big health care data is the next big thing? >> interesting, you talk to silicon valley and they tell you they think a revolution is coming to health care. they tell you health care delivery can be disrupted. they think technology can basically make it more effective, more cost efficient and it's hot here. they pumped $2 billion into health care startups last year, up 40% over 2012. what's interesting is the different fields startups are interested in. >> like what? >> a couple examples. one is sellscope. the old day you had a kid with an earache, you might take him to the emergency room. what they do is, it's a smart phone with an attachment and it gives you a high quality shot of the eardrum. >> whoa, whoa, whoa. i would take a picture -- hold on. i will grab my phone. i will grab my phone. i would have something -- >> you have the little one at home. you think i go to the emergency

room, i will wait for hours potentially. the idea is you take a high quality photo, send it to the physician and maybe send everybody time and money. >> if they don't come in, it's not an ear infection, he's got a cockroach stuffed in there? >> hopefully he knows what's going on. you mentioned another interesting trend, big data. there's another firm, lots of startups involved in that. what they do is compare contrast quality of different services and they have raised $181 million for investors from t. rowe price. that is one to watch. possible ipo this year. >> josh lipton, thank you very much. my pleasure. i got to hang out with you. thank you very much. interesting stories. little sully says hello. i will saunter over this way with all these wires. i feel like robocop. i have 62 different wires on me. sit down to talk to our next guest here. joel marcus, ceo of alexandria real estate equities, r-a-e is the ticker. a lot of your clients are here. how are you reading rents and

demand for commercial properties? >> great to be here. we have a big operation in san francisco and we viewed it as one of the mainstays of this industry. we think that this industry is going to continue a great year into 2014. couple of our top tenants, cellgene, gilead, names you would know, all looking for additional space. we are reading it pretty well. our fourth quarter, we had the highest leasing quarter ever in the history of the company. >> interesting because you're on right after josh was talking about all the venture capital money. that's not accidental. we don't call this serendipity. this was all planned. this is television, professional type stuff. you guys have an announcement today, rolling out sort of a new investment vehicle that you are partnered with around here. the mayor of san francisco's going, what is it. will it matter to investors? >> yes. actually, this is a big thing. digital health which is the intersection of information technology and health care which will revolutionize this really health care system. we are opening a grand opening

of rock health down in mission bay. the mayor will be there. it is a seed stage incubator. they have launched several dozen companies over many years, and companies that will grow up to be great companies in the future. >> why would effectively a real estate company get involved with that? >> well, we are at the intersection of real estate building long term value and great urban campuses like mission bay in san francisco and the health care system, particularly life science, pharma, biotech, a very, very hot and growing industry and one where it's really the only solution to containment of costs. how do we prevent, how do we diagnose and how do we really cure disease. the only way to get there is through this sector. >> analysts i spoke with about your company like the prospects but said that reworking the balance sheets, something you have been heavily involved in, was painful for investors and your stock is down. >> yes, over the past five years we worked through the lehman era

debacle. we were not overleveraged but carried two great different pieces of land, cambridge and mission bay. we now monetized or cash flowing all of mission bay to the tune of about a million square feet. this year we have given guidance for 7% earnings growth, 4% dividend so we expect to deliver a total return of about 11%. if you look at the history of the company, brian, from our ipo in 1997 through the end of the third quarter, we had a 515% return compared to the reit index which is about 333. bes berkshire was 296. >> better than buffett. >> exactly. real estate is a long term play. you can't just look at the short term. last year we actually had a great year, met all of our operational and financial statistics. but we did a bond offering at 3.9% which caused a little delusion and we sold legacy assets and reinvested in cambridge.

short term for long term. >> final question. we have been highlighting the ten year yield lately as it's crept up to 3%, came down a little below it now, but as yields rise, assuming they continue to do so, your 4.2% dividend will look relatively less attractive to investors looking for effectively annuity type income. would that be something you would increase if bond yields continue to go up? >> we have increased the dividend over 28% over the last year. yes, we share future cash flows with our shareholders. i think sophisticated institutional and retail investors are looking for the total return. so if you can deliver 7% earnings growth plus that dividend, you got a double digit return. >> joel marcus, we are always looking for these under the radar names and you guys certainly have been one. thank you very much for joining us on "street signs." mandy, i know joel said he was a fan of the show. so we found him. >> a fan of the show. not just my mother. >> we found the fan.

>> brian, don't go anywhere. we will check in with you later in the show for your final thoughts. i know you have done 12 interviews already today but you've still got a little bit of work. >> something like that. >> something like that. i'm sure it's all been great stuff. still ahead, devastated. those are the words used by target ceo about that massive data breach. coming up, we will talk to the ceo of home shopping network about what they are doing to keep its customers' info safe. and take a look at that baby. bentley's new ride just unveiled. beautiful. we will talk to the company's president about that new car as well as the car makers' recordbreaking year. before we get to that, what's coming up on "the closing bell"? >> we are eyeing that bentley. >> that's right. guys, we have a ton going on down here at the exchange. it's been a pretty rough day for the bulls on wall street. coming up, you will hear the case for why more liquid assets like stocks may actually be killing your long term returns if you hang on to too much of them. >> also, we talk starbucks.

that stock up nearly 40% the past year, down 3% today. but can this stock keep heading higher? we will get both sides of that in a good old-fashioned stock brawl today. also, we will hear from the ceo of medtronices to find out how obamacare and how important changes in the health care industry are impacting the bottom line. >> all that and much more. see you at the top of the hour. ♪ [ bell ringing, applause ] five tech stocks with more than a 10%... change in after-market trading. ♪ all the tech stocks with a market cap... of at least 50 billion... are up on the day. 12 low-volume stocks... breaking into 52-week highs. six upcoming earnings plays... that recently gapped up. [ male announcer ] now the world is your trading floor.

get real-time market scanning wherever you are with the mobile trader app. from td ameritrade. life's an adventure wand it always has been.pp. but your erectile dysfunction - it could be a question of blood flow. cialis tadalafil for daily use helps you be ready anytime the moment's right. you can be more confident in your ability to be ready. and the same cialis is the only daily ed tablet approved to treat ed and symptoms of bph, like needing to go frequently or urgently. tell your doctor about all your medical conditions and medications, and ask if your heart is healthy enough for sexual activity. do not take cialis if you take nitrates for chest pain, as this may cause an unsafe drop in blood pressure. do not drink alcohol in excess with cialis. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, seek immediate medical help for an erection lasting more than 4 hours. if you have any sudden decrease or loss in hearing or vision, or if you have any allergic reactions such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing,

stop taking cialis and get medical help right away. ask your doctor about cialis for daily use and a 30-tablet free trial.

i was devastated. how could this happen to target and it was really a moving moment for me, because -- because we're all about the guests, all about the trust and the relationship. this is what we've built the franchise on. and to have something like this happen was really -- was, you know, was really -- it was really moving. i mean, i'm still shaken by it. >> that was target's ceo gregg steinhafel's exclusive interview with becky quick earlier today on cnbc. so what can retailers do going forward to prevent data breaches and better protect customer data? let's bring in the ceo of hsn and courtney reagan. great to have you with us today. if i'm buying something on home shopping network, i'm using my

credit card. in light of the massive data breach at target and now the hit on neiman kaumarcus as well, wh are you doing to make sure your customers and their sensitive personal information are safe? >> mandy, first of all, this is a very serious issue, not just for our brand but for the retail industry as a whole and for the consumer. as a direct to consumer business, we have invested significant amounts in technology to ensure the security of our 59 million customers. but what we've also done in addition to technology, we have invested significantly in education from everyone from our programmers all the way through the company so they understand the implications of everything they are going to do. and it is priority number one for us to have that trust in our customer. now, as an industry as a whole, we need to be addressing this at a very broad macro level. we need to really look at why we

are the outliners of chip and pin technology and we need to be able to work together. it's certainly a very key topic for us at the national retail federation to address this to ensure the safety of all our constituencies. >> absolutely. it needs to be a top priority. since you brought up the macro picture, i want to get your read on the economy here through your customers' eyes. we have seen a lot of retailers in recent days cutting their guidance. how are things for you from the economy's standpoint? >> so if you look and i think what you're seeing a lot of the fourth quarter results, you know, we had three major focal points that drove our business in the fourth quarter. one, we really invested in mobile and really being able to reach the customer across all eight of our brands in a very seamless way. second, we really focused on proprietary product at value. that doesn't mean a discount. proprietary product at value that i think is very important,

because we're in a world that if it's just a price game, it's not going to happen. then i believe the third that's very different for our business is we invest in experiences, whether it was the launch of keith urban guitars or launched mary j. blige's christmas album. we took an approach that if the spending ceiling is not going to go up, what's the reason for somebody to come visit our brand every day and be able to have that experience. and we did that from hsn all the way through our luxury brand, frontgate. i think it's really important to differentiate yourself today. you've got to be thinking of all of those things. >> mindy, if we think about traffic, the holiday season, we saw traffic at brick and mortar retailers fall double digits, according to shopper track. how are making sure that the consumers that walk out of the retail stores are going to your platform? what's your compelling statement? >> if you think about it, to your point because we don't have stores, it really behooves us to be where our customer is.

and create that trust and create that relationship and create that experience. as i mentioned before, the investments that we've made across all our business, in mobile we were early, we were innovative and if you look at the end of the third quarter, mobile was 12% of our entire business, not just our digital business, and we were trending to 15% by the end of the fourth quarter. so clearly, it's responding. mobile is also the most intimate way you can read your customer. that device is with her every day, whether it's a smartphone or a tablet. so we have mobile exclusives, we created a game on our mobile platforms that you could spin to win every single day, and it's this idea of generosity. what are you doing for your customer not just because you want to sell them something. i can give them ideas, i can give them information and that's what has to differentiate us. as i was telling you earlier, we can't forget that the thing she really buys is product.

you've got to have great product, then we like to say a great story with great storytellers. so we can create that connection and experience. >> hopefully it works for the future, too. >> thank you very much. let's take a look at what the markets are up to to becaus currently losing steam. the dow is off by 140 points. the nasdaq and s&p are down by over 1%. one of the biggest problems -- one of the laggards is the energy sector. the s&p energy sector is down by 1.7% which is tracking what is going on in crude which is down $1.26 right now despite the fact the u.s. dollar is little on the back foot. coming up next, we're going to be bigging in on the bentley boom. the ultra luxury karcarmaker is coming off its best year ever. we'll be speaking with the president of bentley motors when "street signs" returns.

[ man #1 ] we're now in the approach phase. everything looking good. ♪ velocity 1,200 feet per second. [ man #2 ] your looking great to us, eagle. ♪ 2,000 feet. still looking very good. 1,400 feet. ♪ [ male announcer ] funny thing happens when you shoot for the moon. ahh, that's affirmative. [ male announcer ] you get there. you're a go for landing, over. [ male announcer ] the all new cadillac cts, the 2014 motor trend car of the year. (voseeker of the sublime.ro. you can separate runway ridiculousness... from fashion that flies off the shelves. and you...rent from national. because only national lets you choose any car in the aisle... and go. and only national is ranked highest in car rental customer satisfaction by j.d. power. (natalie) ooooh, i like your style.

(vo) so do we, business pro. so do we. go national. go like a pro. you'd do that for me? really? yeah, i'd like that. who are you talking to? uh, it's jake from state farm. sounds like a really good deal. jake from state farm at three in the morning. who is this? it's jake from state farm. what are you wearing, jake from state farm? [ jake ] uh... khakis. she sounds hideous. well she's a guy, so... [ male announcer ] another reason more people stay with state farm. get to a better state. ♪

we're currently down 150 points there on the dow.

we're at session lows. a confluence of factors here. you name it, we got it. lots of bad news on the retail world. the fed saying keep on going with the taper and the energy sector weighing. there's a lot of things going on but this is what we're seeing. 143 points to the downside for thedown. changing topics, bentley motors coming off its best year in the 95-year history. moments ago it unveiled its newest car at the detroit auto show and we're ready to drool. phil below is live with the president of bentley motors. take it away. >> thank you, mandy. if you have a cool $200,000, have we got a car for you. it is the bentley continental gtv-8s and christoph georges who runs bentley u.s. is here with us. this is a car you're seeing great interest in even though you don't start delivering until a couple months from now. >> we are launching this car after the introduction of our

v-8 product line a year and a half ago. it was very successful. now we have a car with a bit more spice, sharper driving and handling. a bit sportier. >> we have the markets dropping lower today and it's been a rough start of the year for investors. how much does the stock market drive the ultra luxury buyer or are they kind of impervious to that because they're buying six or seven cars? >> the economic indicator is always very important to our business simply because it is a sign of confidence to our customers, and the financial crisis a few years ago, the luxury market went totally down, much lower relatively speaking. when things start to be better, customers are coming back. >> the suv, it's not coming out for a while. i think the end of 2015 at the soonest, but you already have 2,000 preorders? >> yes. we have shown our concepts last

year. we knew our customers always asking for an suv from bentley. we saw an opportunity to move to genuine luxury as far as suvs are concerned. we tested the market and we have more than 2,000 preorders. the car will come in 2016. >> christoph georges, the man who runs bentley in the u.s. do you know why he's smiling? coming off a great year. he says the average bentley buyer has six or seven other cars. >> a little factfactoid. >> thanks, guys. coming up next, we're going west. going out to san francisco for some final thoughts from the jpmorgan conference and our very own brian sullivan. ♪ [ male announcer ] this man has an accomplished research and analytical group at his disposal. ♪ but even more impressive

is how he puts it to work for his clients. ♪ morning. morning. thanks for meeting so early. oh, it's not a big deal at all. come on in. [ male announcer ] it's how edward jones makes sense of investing. ♪ where does the united states get most of its energy? is it africa? the middle east? canada? or the u.s.? the answer is... the u.s. ♪ most of america's energy comes from right here at home. take the energy quiz. energy lives here. a body at rest tends to stay at rest... while a body in motion tends to stay in motion. staying active can actually ease arthritis symptoms. but if you have arthritis, staying active can be difficult.

prescription celebrex can help relieve arthritis pain so your body can stay in motion. because just one 200mg celebrex a day can provide 24 hour relief for many with arthritis pain and inflammation. plus, in clinical studies, celebrex is proven to improve daily physical function so moving is easier. celebrex can be taken with or without food. and it's not a narcotic. you and your doctor should balance the benefits with the risks. all prescription nsaids, like celebrex, ibuprofen, naproxen and meloxicam have the same cardiovascular warning. they all may increase the chance of heart attack or stroke, which can lead to death. this chance increases if you have heart disease or risk factors such as high blood pressure or when nsaids are taken for long periods. nsaids, like celebrex, increase the chance of serious skin or allergic reactions or stomach and intestine problems, such as bleeding and ulcers, which can occur without warning and may cause death. patients also taking aspirin and the elderly are at increased risk for stomach bleeding and ulcers. don't take celebrex if you have bleeding in the stomach or intestine, or had an asthma attack, hives,

other allergies to aspirin, nsaids or sulfonamides. get help right away if you have swelling of the face or throat, or trouble breathing. tell your doctor your medical history. and find an arthritis treatment for you. visit celebrex.com and ask your doctor about celebrex. for a body in motion. welcome back to "street signs," everybody. you know what, brian? 12 interviews, one day, and just one man, but you did it out there at the jpmorgan health care conference. >> yeah, and it was not better living through chemistry. it was au naturel. to conclude, we just had an ad for celebrex that i was looking at and it defines the future. we look at demographics and people aging in america, biotech, health care, all the stuff the folks behind us or doing, it's just going to become more and more of a big business story. i love the piece. bentley. alnw, alnylam, the big winner of

the conference. maybe some of their employees will be buying bentleys. that so far in all of our interviews are on cnbc.com t. >> 38% pop. three-week low for the do you right now. full coverage on "the closing bell," which is now. >> and welcome to "the closing bell." i'm kelly evans at the new york stock exchange. >> i'm bill griffeth. another rough day, as you know, on the street for the bulls here. it started this morning from the get-go and it's just been one of those days where he have time you turn around the market is a little bit lower. >> exactly. if you look at the charts and take a name by biojen, we opened near 52-week highs. we're trading down almost 5%. that pretty much traces the entire market. >> nasdaq has been the hardest hit. you see the dow down 150